Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
durvalumab plus tremelimumab
MYSTIC (DT ; all population), 2020
  NCT02453282
RCTmNSCLC - L1 - all populationdurvalumab and tremelimumabplatinum-based doublet chemotherapyfirst-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%372 / 372some concern
inconclusive
    no statistically significant result

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
durvalumab plus tremelimumab
MYSTIC (DT ; PDL1>25%), 2020
  NCT02453282
RCTmNSCLC - L1 - PDL1 positivedurvalumab and tremelimumabplatinum-based doublet chemotherapyfirst-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%163 / 162some concern
inconclusive
  • inconclusive 15 % decrease in deaths (OS) (PE)
  • inconclusive 5 % increase in progression or deaths (PFS) (PE)

mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative

versus Standard of Care (SoC)
durvalumab plus tremelimumab
ARCTIC (DT ; study B ; PDL1<25%), 2020
  NCT02352948
RCTmNSCLC - L2 - PDL1 negativedurvalumab plus tremelimumabstandard of care : erlotinib, gemcitabine or vinorelbinepatients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;174 / 118some concern
inconclusive
  • inconclusive 20 % decrease in deaths (OS) (PE)
  • inconclusive 23 % decrease in progression or deaths (PFS) (PE)